Penitrium Confirms Efficacy of Combination Therapy Targeting "Pseudo-Resistance" in Cancer Treatment
Combination Effect with Daraxonrasib Demonstrated
Prostate Cancer Clinical Trials and U.S. Phase 2 Study Underway
Penitrium Biosciences has released preclinical research results on Penitrium, its novel drug candidate targeting so-called "pseudo-resistance," a phenomenon in which anticancer drugs fail to work properly due to the tumor microenvironment. The company explained that when Penitrium was combined with targeted therapies, immunotherapies, and chemotherapies, anticancer efficacy was enhanced.
On September 14, Penitrium Biosciences held the "2026 Penitrium Global Clinical Symposium" at the Grand Intercontinental Parnas in Seoul, where it presented the preclinical research results along with its global clinical development strategy for Penitrium.
Chairman Won Dong Jo of Penitrium Biosciences is speaking at the '2026 Penitrium Global Clinical Symposium' held on the 14th at the Grand Intercontinental Parnas in Seoul. Photo by Lee Sungmin
View original imageChoi Jin-ho, Distinguished Professor of Chemistry at Dankook University, explained that the tumor microenvironment—composed of cancer-associated fibroblasts (CAF), tumor-associated macrophages (TAM), and the extracellular matrix (ECM)—can serve as a barrier, hindering both anticancer drugs and immune cells from reaching cancer cells. He defined "pseudo-resistance" as a phenomenon in which, although the cancer cells themselves retain drug sensitivity, the surrounding environment reduces treatment efficacy.
Professor Choi stated, "Even if cancer cells remain sensitive to a drug, the formation of a barrier around the tumor can prevent the anticancer agent from reaching its target effectively, resulting in what appears to be clinical resistance."
The organoid study unveiled at the symposium highlighted the combinatorial effect of Penitrium with Daraxonrasib—a RAS-targeted anticancer drug recently approved by the U.S. Food and Drug Administration (FDA). According to the research, in an environment where lung cancer organoids were co-cultured with CAFs, the calculated residual resistance based on cell viability was 89.6%; however, this was reduced to 7.5% after additional administration of Penitrium.
Jang Suhwa, Director of Research Planning at Penitrium Biosciences, explained, "We confirmed that a tumor-suppressive effect was observed when Penitrium was combined with various anticancer drugs, regardless of cancer type or drug class."
Jang Suhwa, Research Planning Director at Penitrium Bio, is explaining the results of the Penitrium combination organoid study at the '2026 Penitrium Global Clinical Symposium' held on the 14th at the Grand InterContinental Parnas in Seoul. Photo by Lee Sungmin
View original imageThe efficacy observed in preclinical studies will next be validated in clinical trials with patients. In Korea, a phase 1 trial is underway in prostate cancer patients, in which Penitrium is added to the standard regimen. In the U.S., the company has received approval for a phase 2a investigational new drug (IND) application targeting patients with solid tumors and is preparing to launch the study.
Ji Eun Lee, Director of Global Clinical Development at Penitrium Biosciences, stated, "The clinical trial is structured to add Penitrium to ongoing anticancer therapies; at the 12-week mark after dosing, we will evaluate safety, tolerability, biomarkers, and radiographic tumor assessments."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jowon Dong, Chairman of Penitrium Biosciences, commented, "If the ceiling in cancer treatment is pseudo-resistance caused by the tumor microenvironment, then we must not only target cancer cells themselves but also independently address pseudo-resistance. We intend to validate in actual cancer patients whether this new approach—combining cancer cell targeting with pseudo-resistance targeting—can break through that ceiling."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.